RecruitingNCT06876610

Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer


Sponsor

Geneplus-Beijing Co. Ltd.

Enrollment

200 participants

Start Date

Mar 15, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to construct an auxiliary diagnostic model for breast cancer by methylation markers. The study will collect blood and tissue samples from participants with breast cancer and benign disease for whole-genome methylation sequencing. It will screen methylation markers and develop a methylation auxiliary diagnosis model to distinguish between breast cancer and non-cancer.


Eligibility

Min Age: 30 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether a blood test that detects cancer-related DNA changes (called cell-free DNA methylation) can help diagnose breast cancer at an earlier stage. **You may be eligible if...** - You have a confirmed diagnosis of breast cancer with known molecular subtype information - You are able to give informed consent - OR you are a healthy volunteer able to give informed consent **You may NOT be eligible if...** - You have had another type of cancer previously or currently - You are pregnant or planning to become pregnant - You have received any cancer treatment (surgery, chemotherapy, radiation, targeted therapy, or immunotherapy) before the blood draw - You have had a blood transfusion in the past month Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06876610


Related Trials